Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTRX-07 Phase 1 MAD Study in Healthy Volunteers and Early AD
NCT06194552Phase 1Completed
- Sponsor
- NeuroTherapia, Inc.
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, double-blind trial of NTRX-07 in Alzheimer's disease (AD) (6 arms), sponsored by NeuroTherapia, Inc. Primary endpoint: Treatment-Related Adverse Events at 2 weeks. Started Sep 2022; status: completed.
02
Drugs
NTRX-07
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06194552.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06194552.